| Ticker: CPTS | 1021 Howard Avenue | |
| Exchange: NASDAQ-National Market | San Carlos, California 94070 | |
| Industry: Manufacturing | (415) 802-7240 |
| Type of Shares: | Common Shares | Filing Date: | 11/30/95 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 2/1/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 3,000,000 | Offer Price: | $14.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.98 | |
| Offering Amount: | $36,000,000 | Selling: | $0.57 | |
| Expenses: | $800,000 | Reallowance: | $0.10 | |
| Shares Out After: | 8,621,728 |
| Manager | Tier | Phone |
| UBS Securities Inc. | Lead Manager | (212) 230-4000 |
| Piper Jaffray Incorporated | Co-manager | (612) 342-6000 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/94 | 9/30/95 | 9/30/94 | 9/30/95 | ||
| Revenue: | $0.39 | $0.19 | $0.25 | Assets: | $7.52 |
| Net Income: | -$3.88 | -$4.11 | -$2.82 | Liabilities: | $17.71 |
| EPS: | -$0.82 | -$0.81 | -$0.61 | Equity: | -$10.19 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The Company designs, develops and markets minimally invasive devices for reproductive medical applications. The Company's initial focus is on improving the diagnosis and treatment of fallopian tube diseases and disorders, primary causes of infertility, and on providing a non-surgical approach to fallopian tube sterilization, the most commonly performed contraceptive procedure worldwide. Conceptus has developed proprietary micro-catheter and guidewire systems that allow physicians to transcervically (through the cervix) access and navigate the full length of the fallopian tubes in a nonsurgical approach. The Company believes that its fallopian tube access systems will facilitate more rapid and accurate diagnosis of fallopian tube diseases and disorders than conventional diagnostic methods, which are known to be inaccurate, leading to more appropriate selection of therapies, and ultimately, improved reproductive outcomes. The Company also believes that its systems will allow many tubal therapies for both infertility and sterilization that are currently performed surgically to be performed transcervically, thereby reducing the cost, trauma and recovery time associated with those therapies. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund clinical research trials, research and development activities, marketing and sales activities, and for working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.